scholarly journals Relationship between CD-8 Expression to Treatment Response in Nasopharyngeal Carcinoma Patient After Neoadjuvant Chemotherapy in Dr. Mohammad Hoesin Hospital Palembang

2022 ◽  
Vol 6 (4) ◽  
Author(s):  
Denny Satria Utama ◽  
Eriza ◽  
Belly Sutopo Wijaya ◽  
Erial Bahar
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Performance Status ◽  
Observational Research ◽  
Primary Tumors ◽  
Significant Relationships ◽  
Significant Difference ◽  
Anti Cancer ◽  
Relationship Of

Background. Nasopharyngeal carcinoma (NPC) is the most common malignancy in head and neck in Indonesia with 19,943 new cases in 2020 resulting 13,399 deaths. Lymphocytes are cells that play a role in the anti-cancer immune response, especially CD-8 T-cells. Neoadjuvant chemotherapy is chemotherapy given before radiotherapy that aims to kill primary tumors and micrometastasis tumors. This study aims to find out the relationship of CD-8 expression to treatment response in NPC undergoing neoadjuvant chemotherapy at Dr. Mohammad Hoesin Hospital Palembang. Methods. This study is an analytical observational research study on a retrospective cohort basis. Data collection from medical records using total sampling in 15 patients pilot study of NPC patients undergoing neoadjuvant chemotherapy and conducted CD-8 examination at ORLHNS polyclinic Dr. Mohammad Hoesin Hospital Palembang from December 2018 to December 2019 that met the criteria of inclusion and exclusion. Results. From 15 samples, the average CD-8 test result before neoadjuvant chemotherapy was 24.54 ng/μL and after neoadjuvant chemotherapy was 193.56 ng/μL. There was a tendency to increase the average CD-8 from before to after completion of neoadjuvan chemotherapy with a statistically significant difference of p =0.001. ROC analysis found CD-8 cut off points is 23.76 ng/μL with an area below the curve is 0.667. There were no significant relationships between CD-8 to performance status and treatment response with p values of 0.289 and 0.219, respectively.  Conclusions. There was a significant change between CD-8 before neoadjuvant chemotherapy and after neoadjuvant chemotherapy with increased CD-8 tendencies and trends from before to after 6 series neoadjuvant chemotherapy with CD-8 cut off points is 23.76 ng/μL. In this study there has not been a significant relationships between CD-8 to performance status and treatment response in NPC patients undergoing neoadjuvant chemotherapy.

Development and Validation of CT-based Radiomics Scores for Prediction of Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer

2019 ◽  
Author(s):  
Kai-Yu Sun ◽  
Hang-Tong Hu ◽  
Shu-Ling Chen ◽  
Jin-Ning Ye ◽  
Guang-Hua Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Validation Cohort ◽  
Clinical Score ◽  
Feature Reduction ◽  
Portal Venous Phase ◽  
Clinical Variables ◽  
Predicting Performance ◽  
Significant Difference

Abstract Background: Neoadjuvant chemotherapy is a promising treatment option for potential resectable gastric cancer, but patients’ responses varied. We aimed to develop and validate a radiomics score (rad_score) to predict the treatment response of neoadjuvant chemotherapy, and to investigate its efficacy in survival stratification. Methods: A total of 106 patients with neoadjuvant chemotherapy before gastrectomy were included (training cohort: n=74; validation cohort: n=32). Radiomics features were extracted from the pre-treatment portal venous-phase CT. After feature reduction, a rad_score was established by Randomized Tree algorithm. A rad_clinical_score was constructed by integrating the rad_score with clinical variables, so was a clinical score by clinical variables only. The three scores were validated regarding their discrimination and clinical usefulness. According to the score thresholds (updated with post-operative clinical variables), patients were stratified into two groups and their survivals were compared.Results: In the validation cohort, the rad_score demonstrated a good predicting performance in treatment response of neoadjuvant chemotherapy (AUC [95% CI] =0.82 [0.67, 0.98]), which was better than the clinical score (based on pre-operative clinical variables) without significant difference (0.62 [0.42, 0.83], P=0.09). The rad_clinical_score could not further improve the performance of rad_score (0.70 [0.51, 0.88], P=0.16). Based on the thresholds of these scores, the high-score groups all achieved better survivals than the low-score groups in the whole cohort (all P<0.001). Conclusion: The rad_score was effective in predicting treatment response of neoadjuvant chemotherapy and stratifying patients’ survival for gastric cancer, which assisted in individualized treatment planning.

Treatment response and survival in patients with pancreatic adenocarcinoma receiving neoadjuvant chemotherapy or chemoradiation.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15715-e15715
Author(s):  
Ahmed Khattab ◽  
Sunita Patruni ◽  
Stephen Abel ◽  
Shaakir Hasan ◽  
Gene Grant Finley ◽  
...  
Keyword(s):  
Overall Survival ◽  
Logistic Regression ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Pathologic Complete Response ◽  
Multivariable Analysis ◽  
Ductal Adenocarcinoma ◽  
Multivariable Logistic Regression ◽  
Predictors Of Response ◽  
Significant Difference

e15715 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Neoadjuvant chemotherapy (NeoChT) and chemoradiation (NeoCRT) have emerged as strategies to optimize resection, but data investigating predictors of treatment response and the overall survival (OS) impact are not well characterized. To investigate the effects of NeoChT/NeoCRT on primary tumor/nodal downstaging and OS, we analyzed the national cancer database (NCDB). Methods: We queried the NCDB for patients with PDAC receiving NeoChT/NeoCRT. Patients were classified as responders (T and/or N downstage), nonresponders (mixed/no response) and progressors (T and/or N upstage). Multivariable logistic regression identified predictors of response. Univariable and multivariable analyses identified characteristics predictive of OS. Results: 2,028 patients with PDAC receiving NeoChT/NeoCRT were analyzed. Univariable analysis of responders (n = 790) vs. nonresponders/progressors (n = 1,238) demonstrated a significant difference in median OS at 29.1 months vs. 25.3 months and 3-year overall survival of 40% vs. 34% [p = 0.006; HR: 0.95 (95% CI: 0.84-1.08)] respectively. When compared independently to both responders and nonresponders, progressors had a significantly decreased 3-year OS at 31% vs 40% and 37% respectively [p = 0.003; HR: 0.82 (95% CI: 0.70-0.96)]. Predictors of response on multivariable logistic regression included receipt of multiagent chemotherapy and receipt of NeoCRT. Only NeoCRT predicted for pathologic complete response (pCR). Multivariable analysis of patients with pCR demonstrated a trend towards increased OS (p = .08). Conclusions: Our results suggest that both response and progression following neoadjuvant therapy may predict for longer and shorter OS respectively. Randomized, prospective studies are needed to further validate these findings. [Table: see text]

Surgical outcomes and rate of pathological response in resectable/borderline resectable pancreatic cancer patients undergoing neoadjuvant gemcitabine/nab-paclitaxel versus FOLFIRINOX: A retrospective institutional analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16247-e16247
Author(s):  
Abraham Attah Attah ◽  
Saleha Rizwan ◽  
Khaled Alhamad ◽  
Micheal Turk ◽  
Palash Asawa ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Surgical Resection ◽  
Locally Advanced ◽  
Small Sample ◽  
Ductal Adenocarcinoma ◽  
Categorical Variables ◽  
Adjuvant Setting ◽  
Borderline Resectable ◽  
Significant Difference

e16247 Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors, predicted to become the second leading cause of cancer related death in some regions of the world. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Only about 20% of the cases are diagnosed early enough to undergo surgical resection leading to complete remission. While chemotherapy has an established role in the setting of metastatic disease, utilizing it in the neo-adjuvant setting has been adopted by most institutes for resectable/ borderline resectable cases. Ongoing trials are exploring the use of different regimens in the neo-adjuvant setting. The aim of our study was to identify patients with resectable/borderline resectable PDAC undergoing neoadjuvant chemotherapy and differences in surgical outcome based on the regimen received i.e gemcitabine/ nab-Paclitaxel vs FOLFIRINOX. Methods: A retrospective review was conducted of all patients diagnosed with PDAC from 2017-2019 at Allegheny General Hospital. Data analysis was completed using IBM SPSS v23. Summary statistics were presented using percentages for categorical variables and medians with interquartile ranges for continuous variables. Results: Out of 121 patients who received and completed treatment in our institution, 30 underwent neoadjuvant chemotherapy treatment followed by surgical intervention. 21 (70%) patients were found to be borderline resectable, 8 (27%) patients were resectable and 1 patient had locally advanced PDAC. 16 (53%) patients received FOLFIRINOX compared to 13 (43%) patients received gem/nab-paclitaxel. Among patients who received neoadjuvant FOLFIRINOX, 5 out of 16 (31%) patients had moderate to significant treatment response at the time of surgery compared to 7 out of 13 (54%) patients who received gemcitabine/nab-paclitaxel. Conclusions: Our study revealed no significant difference (p=0.21) between the patients who received neoadjuvant gemcitabine/nab-paclitaxel vs FOLFIRINOX in terms of treatment response assessed pathologically at the time surgical resection. We recognize the limitations of our study in terms of it being a retrospective analysis with a small sample size and therefore further prospective and randomized controlled trials are needed to determine the most suitable and effective regimen in the neoadjuvant setting for resectable/borderline resectable PDAC patients. Response to treatment among different chemotherapy groups.[Table: see text]

scholarly journals CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer

2020 ◽  
Author(s):  
Kai-Yu Sun ◽  
Hang-Tong Hu ◽  
Shu-Ling Chen ◽  
Jin-Ning Ye ◽  
Guang-Hua Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Response ◽  
Validation Cohort ◽  
Clinical Score ◽  
Feature Reduction ◽  
Portal Venous Phase ◽  
Clinical Variables ◽  
Significant Difference ◽  
Response To Neoadjuvant Chemotherapy

Abstract Background: Neoadjuvant chemotherapy is a promising treatment option for potential resectable gastric cancer, but patients’ responses vary. We aimed to develop and validate a radiomics score (rad_score) to predict treatment response to neoadjuvant chemotherapy and to investigate its efficacy in survival stratification.Methods: A total of 106 patients with neoadjuvant chemotherapy before gastrectomy were included (training cohort: n=74; validation cohort: n=32). Radiomics features were extracted from the pre-treatment portal venous-phase CT. After feature reduction, a rad_score was established by Randomised Tree algorithm. A rad_clinical_score was constructed by integrating the rad_score with clinical variables, so was a clinical score by clinical variables only. The three scores were validated regarding their discrimination and clinical usefulness. The patients were stratified into two groups according to the score thresholds (updated with post-operative clinical variables), and their survivals were compared. Results: In the validation cohort, the rad_score demonstrated a good predicting performance in treatment response to the neoadjuvant chemotherapy (AUC [95% CI] =0.82 [0.67, 0.98]), which was better than the clinical score (based on pre-operative clinical variables) without significant difference (0.62 [0.42, 0.83], P=0.09). The rad_clinical_score could not further improve the performance of the rad_score (0.70 [0.51, 0.88], P=0.16). Based on the thresholds of these scores, the high-score groups all achieved better survivals than the low-score groups in the whole cohort (all P<0.001).Conclusion: The rad_score that we developed was effective in predicting treatment response to neoadjuvant chemotherapy and in stratifying patients with gastric cancer into different survival groups. Our proposed strategy is useful for individualised treatment planning.

Premilinary survival results and potential beneficiaries for locally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6030-6030
Author(s):  
Mei Feng ◽  
Jinyi Lang ◽  
Lu Li ◽  
Yecai Huang ◽  
Peng Xu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Concurrent Chemoradiotherapy ◽  
Clinical Stage ◽  
Univariate Analysis ◽  
Locally Advanced ◽  
Stage Iii ◽  
Significant Difference

6030 Background: Neoadjuvant is a promising chemotherapy modality for recurrent nasopharyngeal carcinoma (NPC). However, there is still controversy for locally advanced NPC. We study the survival results of locally advanced NPC treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NACT) retrospectively, and to explore the potential beneficiaries. Methods: 147 stage III-IVa+b NPC treated with IMRT were included and divided into two groups. NACT group (76) received 2-3 cycles of neoadjuvant chemotherapy with TP or TPF, and then 2-3 cycles of platinum-based chemoradiotherapy (CCRT). CCRT group (71) received 3 cycles of platinum-based chemoradiotherapy. TNM stage, age and whole blood count before treatment were all collected. The stratified analysis was used for distinguishing the potential beneficiaries. Results: median follow-up time was 30 months. For all patients, the 3-year LRRFS, DMFS and OS in NACT and CCRT were 94.5%, 96.8%; 85.8%, 82.8% and 81.6%, 83.4% respectively ( p> 0.05). For stage III patients, the 3-year LRRFS, DMFS and OS were 95.2%, 97.3%; 91.4%, 84.6% and 86.3%, 82.1% respectively ( p= 0.38, p= 0.15, p= 0.58). Though there was no statistical significance, DMFS in NACT was better than it in CCRT. However, for stage IV, the survival rate had no significant difference. The incidence of grade 3-4 bone marrow suppression was higher in NACT ( p= 0.007), and the other toxicities were similar. Univariate analysis showed the percentages of neutrophil and neutrophil-to-lymphocyte ratio (NLR) were significantly correlated with OS ( p= 0.031, p= 0.049). N and clinical stage were the adverse prognostic factors for OS ( p= 0.025, p= 0.007) and DMFS ( p= 0.018, p= 0.001). Clinical stage was the prognostic factors for OS and DMFS in multivariate analyses ( p= 0.019, p= 0.01). Conclusions: NACT had a comparable survival results and tolerable toxicity with CCRT for locally advanced NPC. Stage III might be the potential beneficiaries from NACT, especially for DMFS. Percentages of neutrophil and NLR might be the new adverse prognostic factor for OS. Clinical stage was still the prognostic factor for OS and DMFS.

scholarly journals Association between Foxp3 Tumor Infiltrating Lymphocyte Expression and Response After Chemoradiation in Nasopharyngeal Carcinoma

2021 ◽  
Vol 9 (A) ◽  
pp. 1285-1291
Author(s):  
Lisnawati Lisnawati ◽  
Yayi Dwina Billianti ◽  
Amelia Fossetta Manatar
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Treatment Response ◽  
Foxp3 Expression ◽  
Cross Sectional Study ◽  
Surface Epithelium ◽  
Cross Sectional ◽  
Factors Affecting ◽  
Significant Difference ◽  
The Relationship ◽  
Anatomical Pathology

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a carcinoma originating from the surface epithelium of the nasopharynx with the highest incidence in China and South East Asia. Currently, many researchers are developing tumor microenvironment which can be assessed by tumor-infiltrating lymphochyte, and its association with treatment response in several tumors, including NPC. Foxp3, known as a regulatory T cell (Treg) marker, plays a role in the immunoregulatory environment of tumor cells and can be used as a prognostic factor. The relationship between Foxp3 expression and treatment response is considered as one of the factors affecting the prognosis of NPC. AIM: This study aims to determine the relationship between Foxp3 expression and treatment response in NPC. MATERIALS AND METHODS: A cross-sectional study was done to analyze the association between Foxp3 and treatment response in NPC. This study included 60 samples who were diagnosed with non-keratinizing NPC at the Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital from January 2018 until December 2020. Immunohistochemistry was done to evaluate the expression of Foxp3. Foxp3 expression was evaluated in the intratumoral and peritumoral areas. RESULTS: Among 60 patients, the number of males were more than females (66.7%, 33.3%, respectively) with a ratio of 2:1. There was statistically significant difference between intratumoral and total Foxp3 expression and treatment response (p < 0.05, p = 0.001, respectively); however, no significant differences found between peritumoral Foxp3 expression and treatment response (p = 0.114). CONCLUSION: Foxp3 expression had a statistically significant relationship with response therapy after chemoradiation.

Relationship of Clients' Sex to Effective Vocational Counseling by Male Counselors

1974 ◽  
Vol 39 (1) ◽  
pp. 653-654
Author(s):  
David A. Bundy ◽  
David J. Hebert
Keyword(s):  
Vocational Counseling ◽  
Occupational Choices ◽  
Male Clients ◽  
Significant Relationships ◽  
Significant Difference ◽  
Relationship Of ◽  
Vocational Aspirations ◽  
Moderate Magnitude

The findings indicate that there is no significant difference in male counselors' perception of the vocational aspirations of their female and their male clients. The over-all findings indicate that male counselors are reasonably perceptive of the vocational aspirations of their clients; 90% of the counselors participating in the study achieved significant relationships of moderate magnitude between their clients' occupational choices and their perceptions of their choice.

scholarly journals THE RELATIONSHIP BETWEEN THE STAGE OF NASOPHARYNGEAL CARCINOMA WITH ANEMIA AND NUTRITIONAL STATUS IN WEST NUSA TENGGARA GENERAL HOSPITAL

2020 ◽  
Vol 2 (01) ◽  
pp. 15-17
Author(s):  
Ni Ketut Susilawati ◽  
Hamsu Kadriyan ◽  
Wayan Putu Sutirtayasa
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Nutritional Status ◽  
Malignant Tumors ◽  
Nasopharyngeal Cancer ◽  
P Value ◽  
Cross Sectional ◽  
Normality Test ◽  
Significant Difference ◽  
Relationship Of ◽  
The Relationship

Introduction: Nasopharyngeal carcinoma is the most common malignant tumor in the ENT-HNS were the highest of all malignant tumors of the head and neck. Malnutrition and cachexia is a common problem in cancer patients and impact on quality of life and survival. Anemia is a major problem in patients with nasopharyngeal cancer receiving chemotherapy or radiotherapy. Objective: Determine the relationship of nasopharyngeal carcinoma stage with anemia and nutritional status. Material and methods: This study used cross sectional analytic method. Data were obtained from medical records of patients with nasopharyngeal carcinoma who were treated in province hospital West Nusa Tenggara period January 2018 to December 2018. Data collected include the identity, diagnosis, hemoglobin value, weight and height. Having analyzed the data collected are looking for is there a relationship between stage nasopharyngeal carcinoma with anemia and nutritional status. Results: In this study, Shapiro-Wilk normality test. Anova is then performed to analyze the relationship stage nasopharyngeal carcinoma with anemia status obtained 95% CI, p value 0.847, there is no difference between stage nasopharyngeal carcinoma with anemia. Kruskal Wallis test to analyze the relationship with BMI (body mass index) with stage nasopharyngeal carcinoma obtained 95% CI, p value 0.565. There is no difference in BMI with stage nasopharyngeal carcinoma. Conclusion: There is a tendency to lower Hb in patients with nasopharyngeal cancer further stage although there is no significant difference between each stage. The same thing was found in BMI, BMI decreased tendency in patients with advanced nasopharyngeal cancer although there was no statistically significant difference.

Sign in / Sign up

Export Citation Format

Share Document